Nitric Oxide Gas Inhalation for Severe Acute Respiratory Syndrome in COVID-19.
Status:
Withdrawn
Trial end date:
2022-03-01
Target enrollment:
Participant gender:
Summary
The investigators will enroll 102 patients with a confirmed diagnosis of COVID-19. Patients
will be randomized to receive either inhaled nitric oxide (per protocol) or placebo. ICU
Standards of care will be the institution's own protocols (such as ventilation strategies and
use and dose of antivirals and antimicrobials, steroids, inotropic and vasopressor agents).
Phase:
Phase 2
Details
Lead Sponsor:
Xijing Hospital
Collaborators:
Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico Massachusetts General Hospital